ReviewBest practice & research. Clinical gastroenterology2011
Pathogenesis of primary sclerosing cholangitis.
Review in Best practice & research. Clinical gastroenterology, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 61 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
61 citing papers in PubMed, 3 syntheses or guidelines pooled it, 133 citations in OpenAlex.
- Clinical and Immunological Features, Genetic Variants, and Outcomes of Patients with CD40 Deficiency.Journal of clinical immunology · 2023Pooled it
- Consensus guidelines: best practices for detection, assessment and management of suspected acute drug-induced liver injury occurring during clinical trials in adults with chronic cholestatic liver disease.Alimentary pharmacology & therapeutics · 2020Guideline
- Clinical guidelines for primary sclerosing cholangitis 2017.Journal of gastroenterology · 2018Guideline
- Article
- Genetic evidence supports primary biliary cholangitis as a risk factor for lacunar stroke.iScience · 2025Article
- Microbiome and gut-liver interactions: From mechanisms to therapies.World journal of gastroenterology · 2025Review
- Liver immunology: Biological role and clinical significance.World journal of hepatology · 2025Review
- Off-target autophagy disruption associated with a novel liver toxicity in dogs for a highly basic heterobifunctional protein degrader.Frontiers in pharmacology · 2025Article
- The Association Between Primary Sclerosing Cholangitis and Microscopic Colitis: A Systematic Review.Cureus · 2024Review
- Machine Learning Identifies Key Proteins in Primary Sclerosing Cholangitis Progression and Links High CCL24 to Cirrhosis.International journal of molecular sciences · 2024Article
- The Role of CCL24 in Primary Sclerosing Cholangitis: Bridging Patient Serum Proteomics to Preclinical Data.Cells · 2024Article
- Human Hepatocellular response in Cholestatic Liver Diseases.Organogenesis · 2023Article
- Differential Diagnosis: Hepatic Complications in Inborn Errors of Immunity.Journal of clinical medicine · 2023Review
- Non-steroidal FXR agonist cilofexor improves cholestatic liver injury in theJHEP reports : innovation in hepatology · 2023Article
- JNKs protect from cholestatic liver disease progression by modulating Apelin signalling.JHEP reports : innovation in hepatology · 2023Article
- Immune-mediated cholangiopathies in children: the need to better understand the pathophysiology for finding the future possible treatment targets.Frontiers in immunology · 2023Review
- The Role of Sex in Acute and Chronic Liver Damage.International journal of molecular sciences · 2022Review
- Maternal obesogenic diet enhances cholestatic liver disease in offspring.Journal of lipid research · 2022Article
- Human Leukocyte Antigen Profile Predicts Severity of Autoimmune Liver Disease in Children of European Ancestry.Hepatology (Baltimore, Md.) · 2021Article
- Analysis of the Clinical Course of Primary Sclerosing Cholangitis in Paediatric Population-Single Center Study.Medicina (Kaunas, Lithuania) · 2021Article
1 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
Abstract
Primary sclerosing cholangitis (PSC) represents a chronic cholestatic liver disease with fibroobliterative sclerosis of intra- and/or extrahepatic bile ducts, eventually leading to biliary cirrhosis. The association with human leukocyte antigen (HLA) and non-HLA haplotypes and the presence of autoantibodies in sera of PSC patients support a crucial role for immune-mediated mechanisms in the initiation and progression of PSC. The strong clinical association between PSC and inflammatory bowel diseases led to intriguing pathogenetic concepts, in which the inflamed gut with translocation of bacterial products and homing of gut-primed memory T lymphocytes via aberrantly expressed adhesion molecules plays a fundamental role. Genetically or chemically modified bile composition was shown to induce sclerosing cholangitis and liver fibrosis in a number of animal models ("toxic bile concept"). The potential role of vascular injury with ischemia of bile duct epithelium cells in the development of sclerosing cholangitis is supported by animal models of endothelial cell injury showing close morphological similarities with human PSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.